Steven L. Hoerter
Currently, Steven L. Hoerter is President & Chief Executive Officer at Deciphera Pharmaceuticals, Inc. and President, Director & Chief Executive Officer at Deciphera Pharmaceuticals LLC (a subsidiary of Deciphera Pharmaceuticals, Inc.). Mr. Hoerter is also on the board of Oric Pharmaceuticals, Inc.
In the past Mr. Hoerter was Chief Commercial Officer for Agios Pharmaceuticals, Inc., Chief Commercial Officer & Executive VP for Clovis Oncology, Inc., Director-Pipeline Development at Genentech, Inc. and GM, Head-Sub-Saharan Africa & Indian Ocean Region at Roche Group.
Mr. Hoerter received an undergraduate degree from Bucknell University, an MBA from the University of Tilburg and a graduate degree from Purdue University.
|03/21/2023||7,500||Disposition at $15.57 per share.||116,775|
|02/14/2023||30,045||Disposition at $16 per share.||480,720|
|03/21/2022||3,150||Derivative/Non-derivative trans. at $9.11 per share.||28,697|
|03/18/2021||2,450||Derivative/Non-derivative trans. at $43.19 per share.||105,816|
|03/18/2021||700||Derivative/Non-derivative trans. at $42.39 per share.||29,673|
|01/21/2021||1,078||Derivative/Non-derivative trans. at $25.4 per share.||27,381|
|08/20/2020||187||Derivative/Non-derivative trans. at $25.4 per share.||4,749|
|07/20/2020||188||Derivative/Non-derivative trans. at $25.4 per share.||4,775|
|06/18/2020||187||Derivative/Non-derivative trans. at $25.4 per share.||4,749|
|05/28/2020||188||Derivative/Non-derivative trans. at $25.4 per share.||4,775|
|04/21/2020||187||Derivative/Non-derivative trans. at $25.4 per share.||4,749|
|03/19/2020||520||Derivative/Non-derivative trans. at $39.98 per share.||20,790|
|03/19/2020||2,164||Derivative/Non-derivative trans. at $39.22 per share.||84,873|
|03/19/2020||4,230||Derivative/Non-derivative trans. at $38.26 per share.||161,840|
|03/19/2020||1,012||Derivative/Non-derivative trans. at $36.88 per share.||37,323|
|03/19/2020||4,494||Derivative/Non-derivative trans. at $35.78 per share.||160,796|
|03/18/2020||2,250||Derivative/Non-derivative trans. at $25.4 per share.||57,150|
|03/18/2019||30,000||Award at $0 per share.||0|
|03/18/2019||22,000||Award at $0 per share.||0|